



(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 December 2000 (21.12.2000)

PCT

(10) International Publication Number
WO 00/77044 A1

(51) International Patent Classification⁷: C07K 14/47, G01N 33/68, C07K 16/18

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/FI00/00540

(22) International Filing Date: 15 June 2000 (15.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 991369 15 June 1999 (15.06.1999) FI

(71) Applicant and

(72) Inventor: HOLTHÖFER, Harry [FI/FI]; The Haartman Institute, Department of Bacteriology and Immunology, PB 21 (Haartmaninkatu 3), FIN-00014 University of Helsinki (FI).

(74) Agent: BORENIUS & CO OY AB; Kansakoulukuja 3, FIN-00100 Helsinki (FI).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/77044 A1

(54) Title: USE OF SOLUBLE PROTEIN MOLECULES EXPRESSED BY THE PANCREAS AND KIDNEY GLOMERULUS

(57) Abstract: The present invention is related to the of soluble nephrin-like molecules expressed by pancreas and kidney and nucleic acid sequences encoding said nephrin-like molecules, including a human nephrin encoding cDNA, as well as binding substances, capable of specifically recognizing and binding said nephrin-like molecules. The molecules are useful for manufacturing means for diagnostic determination, screening susceptibility of, prophylactic and therapeutic treatment of diabetic and other nephropathies and of diabetes mellitus and other inflammatory and neoplastic pancreatic diseases. The invention is further characterized by the fact that the soluble nephrin-like molecules, binding substances specifically recognizing said soluble nephrin-like molecules can be used to make the diagnostic evaluation from a blood, serum and/or urine sample.